AstraZeneca and Eli Lilly’s Alzheimer’s treatment to be fast tracked
AstraZeneca and Eli Lilly have received US Food and Drug Administration (FDA) fast track designation for the development of a treatment for Alzheimer’s.
The companies made the announcement yesterday, August 22.
The FDA’s fast track programme is designed to expedite the development of new therapies that treat serious conditions.
Craig Shering, project lead in global medicines development at AstraZeneca, said: “The fast track designation in the US for this promising potential therapy reinforces the ambition of the AstraZenaca-Lilly BACE Alliance to advance science for patients and their families managing this devastating illness.”
Phyllis Ferrell, vice president at Eli Lilly, added: “We are pleased that the FDA places a high priority on the development of drugs that target Alzheimer’s disease, one of the most critical health issues of our time.”
AstraZeneca and Eli Lilly agreed to develop and commercialise the Alzheimer's treatment back in 2014, with Eli Lilly leading clinical development and AstraZeneca responsible for manufacturing.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk